Top

Published in:

01-08-2011 | Original Article

The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations

Authors: Antonia Tsallas, John Jackson, Helen Burt

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2011

Abstract

Superficial bladder cancer occurs in the urothelial layer of the bladder and is usually treated by transurethral resection and chemotherapy. Although the bladder is well suited for intravesical chemotherapy, effective drug delivery is restricted by urine dilution and poor drug uptake by bladder tissues during a 2 h instillation. In this study, freshly excised pig bladder sections were mounted on Franz diffusion cells and treated with anticancer drugs paclitaxel (PTX) and docetaxel (DTX) formulated in diblock copolymer (methoxy poly(ethylene glycol)-block-poly (D,L-lactic acid) (MePEG-PDLLA) and methoxy poly(ethylene glycol)-block-poly(caprolactone) (MePEG-PCL) nanoparticles for 2 h. The bladder sections were then frozen, cryosectioned (60-μm sections) and the amount of ³H drug taken up into each section was determined using liquid scintillation counting. Tissue concentration versus tissue depth profiles were obtained for all drug formulations and drug exposure obtained from area-under-the-curve (AUC) calculations. PTX or DTX loaded in MePEG-PDLLA micelles produced significantly higher urothelial tissue levels and greater bladder wall exposures compared to their commercial formulations, Cremophor EL/ethanol (PTX) or Tween 80 (DTX). The results of this study support the use of diblock copolymer micellar PTX or DTX formulations as they allow for improved drug penetration of bladder tissues compared to commercial formulations for taxane delivery to superficial bladder tumors.

Au JL, Badalament RA, Wientjes MG, Young DC, Warner JA, Venema PL, Pollifrone DL, Harbrecht JD, Chin JL, Lerner SP, Miles BJ (2001) Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 93:597–604PubMedCrossRef

Au JL, Kalns J, Gan Y, Wientjes MG (1997) Pharmacologic effects of paclitaxel in human bladder tumors. Cancer Chemother Pharmacol 41:69–74PubMedCrossRef

Badalament RA, Farah RN (1997) Treatment of superficial bladder cancer with intravesical chemotherapy. Semin Surg Oncol 13:335–341PubMedCrossRef

Barlow LJ, McKiernan JM, Benson MC (2009) The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. World J Urol 27:331–335PubMedCrossRef

Boring CC, Squires TS, Tong T, Montgomery S (1994) Cancer statistics, 1994. CA Cancer J Clin 44:7–26PubMedCrossRef

Bouffioux C, Kurth KH, Bono A, Oosterlinck W, Kruger CB, De Pauw M, Sylvester R (1995) Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European organization for research and treatment of cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European organization for research and treatment of cancer genitourinary group. J Urol 153:934–941PubMedCrossRef

Burt HM, Zhang X, Toleikis P, Embree L, Hunter W (1999) development of copolymers of poly(DL-lactide) and methoxypolyethylene glycol as micellar carriers of paclitaxel. Colloids Surf B Biointerfaces 16:161–171CrossRef

Chen D, Song D, Wientjes MG, Au JL (2003) Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel. Clin Cancer Res 9:363–369PubMed

Dalton JT, Wientjes MG, Badalament RA, Drago JR, Au JL (1991) Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res 51:5144–5152PubMed

10.

De Ascentiis A, De Grazia J, Bowman C, Colombo P, Peppas NA (1995) Mucoadhesion of poly(2-hydroxyethyl methacrylate) is improved when linear poly(ethylene oxide) chains are added to the polymer network. J Control Release 33:197–201CrossRef

11.

Galabova D, Tuleva B, Spasova D (1996) Permeabilization of Yarrowia lipolytica cells by Triton X-100. Enzyme Microb Technol 18:18–22CrossRef

12.

Gref R, Luck M, Quellec P, Marchand M, Dellacherie E, Harnisch S, Blunk T, Muller RH (2000) ‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces 18:301–313PubMedCrossRef

13.

Hadaschik BA, ter Borg MG, Jackson J, Sowery RD, So AI, Burt HM, Gleave ME (2008) Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer. BJU Int 101:1347–1355PubMedCrossRef

14.

Highley MS, van Oosterom AT, Maes RA, De Bruijn EA (1999) Intravesical drug delivery. Pharmacokinetic and clinical considerations. Clin Pharmacokinet 37:59–73PubMedCrossRef

15.

Kerec M, Bogataj M, Veranic P, Mrhar A (2005) Permeability of pig urinary bladder wall: the effect of chitosan and the role of calcium. Eur J Pharm Sci 25:113–121PubMedCrossRef

16.

Knemeyer I, Wientjes MG, Au JL (1999) Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment. Cancer Chemother Pharmacol 44:241–248PubMedCrossRef

17.

Konsoula R, Barile FA (2005) Correlation of in vitro cytotoxicity with paracellular permeability in Caco-2 cells. Toxicol In Vitro 19:675–684PubMedCrossRef

18.

Laudano MA, Barlow LJ, Murphy AM, Petrylak DP, Desai M, Benson MC, McKiernan JM (2010) Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy. Urology 75:134–137PubMedCrossRef

19.

Lee WK, Park KD, Kim YH, Suh H, Park JC, Lee JE, Sun K, Baek MJ, Kim HM, Kim SH (2001) Improved calcification resistance and biocompatibility of tissue patch grafted with sulfonated PEO or heparin after glutaraldehyde fixation. J Biomed Mater Res 58:27–35PubMedCrossRef

20.

Letchford K, Liggins R, Burt H (2008) Solubilization of hydrophobic drugs by methoxy poly(ethylene glycol)-block-polycaprolactone diblock copolymer micelles: theoretical and experimental data and correlations. J Pharm Sci 97:1179–1190PubMedCrossRef

21.

Letchford K, Liggins R, Wasan KM, Burt H (2009) In vitro human plasma distribution of nanoparticulate paclitaxel is dependent on the physicochemical properties of poly(ethylene glycol)-block-poly(caprolactone) nanoparticles. Eur J Pharm Biopharm 71:196–206PubMedCrossRef

22.

Malmstrom PU (2003) Intravesical therapy of superficial bladder cancer. Crit Rev Oncol Hematol 47:109–126PubMedCrossRef

23.

McKiernan JM, Masson P, Murphy AM, Goetzl M, Olsson CA, Petrylak DP, Desai M, Benson MC (2006) Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol 24:3075–3080PubMedCrossRef

24.

Mugabe C, Hadaschik BA, Kainthan RK, Brooks DE, So AI, Gleave ME, Burt HM (2009) Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy. BJU Int 103:978–986PubMedCrossRef

25.

Nativ O, Aronson M, Medalia O, Moldavsky T, Sabo E, Ringel I, Kravtsov V (1997) Anti-neoplastic activity of paclitaxel on experimental superficial bladder cancer: in vivo and in vitro studies. Int J Cancer 70:297–301PubMedCrossRef

26.

Oosterlinck W, Kurth KH, Schroder F, Bultinck J, Hammond B, Sylvester R (1993) A prospective European organization for research and treatment of cancer genitourinary group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149:749–752PubMed

27.

Rangel C, Niell H, Miller A, Cox C (1994) Taxol and taxotere in bladder cancer: in vitro activity and urine stability. Cancer Chemother Pharmacol 33:460–464PubMedCrossRef

28.

Shen Z, Shen T, Wientjes MG, O’Donnell MA, Au JL (2008) Intravesical treatments of bladder cancer: review. Pharm Res 25:1500–1510PubMedCrossRef

29.

Soler AP, Miller RD, Laughlin KV, Carp NZ, Klurfeld DM, Mullin JM (1999) Increased tight junctional permeability is associated with the development of colon cancer. Carcinogenesis 20:1425–1431PubMedCrossRef

30.

Song D, Wientjes MG, Au JL (1997) Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother Pharmacol 40:285–292PubMedCrossRef

31.

Sylvester RJ, Oosterlinck W, van der Meijden AP (2004) A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171:2186–2190, quiz 2435

32.

Tolley DA, Parmar MK, Grigor KM, Lallemand G, Benyon LL, Fellows J, Freedman LS, Hall RR, Hargreave TB, Munson K, Newling DW, Richards B, Robinson MR, Rose MB, Smith PH, Williams JL, Whelan P (1996) The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 155:1233–1238PubMedCrossRef

33.

Tringali G, Lisi L, Bettella F, Renier D, Di Stasi SM, Navarra P (2008) The in vitro rabbit whole bladder as a model to investigate the urothelial transport of anticancer agents The ONCOFID-P paradigm. Pharmacol Res 58:340–343PubMedCrossRef

34.

Wientjes MG, Badalament RA, Au JL (1996) Penetration of intravesical doxorubicin in human bladders. Cancer Chemother Pharmacol 37:539–546PubMedCrossRef

35.

Wirth M, Plattner VE, Gabor F (2009) Strategies to improve drug delivery in bladder cancer therapy. Expert Opin Drug Deliv 6:727–744PubMedCrossRef

36.

Zhang X, Jackson J, Burt HM (1996) Development of amphiphilic diblock copolymers as micellar carriers of taxol. Int J Pharm 132:195–206CrossRef

Title: The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations
Authors: Antonia Tsallas
John Jackson
Helen Burt
Publication date: 01-08-2011
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 2/2011
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-010-1499-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Antitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase

Cytotoxic responses to N-(4-hydroxyphenyl)retinamide in human pancreatic cancer cells

Determination of 5-fluorouracil and dihydrofluorouracil levels by using a liquid chromatography–tandem mass spectrometry method for evaluation of dihydropyrimidine dehydrogenase enzyme activity

A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer

The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice

The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models

Keynote webinar | Spotlight on antibody–drug conjugates in cancer